Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO
· Real-Time Price · USD
1.98
-0.06 (-2.94%)
At close: Aug 15, 2025, 3:59 PM
2.02
2.28%
After-hours: Aug 15, 2025, 07:41 PM EDT
Aptevo Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -6.2M | -6.41M | -6.31M | -5.1M | -5.88M | -6.83M | -6.2M | -6.33M | -7.95M | 2.77M | -4.64M | -7.64M | 28.01M | -7.7M | -6.27M | -7M | -7.93M | -7.26M |
Depreciation & Amortization | 49K | 61K | 71K | 84K | 91K | 106K | 116K | 123K | 150K | 178K | 161K | 222K | 276K | 242K | 260K | 296K | 299K | 289K |
Stock-Based Compensation | -163K | 180K | -72K | 149K | 273K | 719K | 358K | 455K | 465K | 915K | 357K | 359K | 485K | 601K | 178K | 319K | 572K | 574K |
Other Working Capital | -274K | 406K | 230K | -529K | 245K | 284K | -213K | -409K | 1.42M | 909K | -2.83M | -667K | 2.07M | 848K | -81K | -1.35M | -7K | 33.51M |
Other Non-Cash Items | n/a | -814K | n/a | -1.63M | 1.33M | 1.86M | 494K | 778K | -349K | 10K | 24K | -28K | -35.58M | 1.69M | 2.25M | 2.03M | 2.06M | 297K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -201K | -778K | 349K | n/a | n/a | n/a | n/a | n/a | n/a | -1K | n/a | 5K |
Change in Working Capital | -775K | 406K | 554K | 1.28M | -634K | -642K | 176K | -485K | 2.53M | 690K | -1.84M | 195K | 3.74M | 50K | -301K | -892K | -49K | -1.41M |
Operating Cash Flow | -7.09M | -6.58M | -5.76M | -5.22M | -6.15M | -6.65M | -5.25M | -6.24M | -4.8M | 4.57M | -5.94M | -6.9M | -3.07M | -5.12M | -3.88M | -5.24M | -5.05M | -7.5M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -25K | -4K | -25K | n/a | -118K | -13K | -391K | -191K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -25K | -4K | -25K | n/a | -118K | -13K | -391K | -191K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3.47M | -500K | -500K | -500K | -10.77M | n/a | n/a | n/a | -10.55M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -4K | 10.23M | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | -8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | 5.56M | n/a | -1K | -3K | -2K | 3.15M | n/a | -8K | 6.5M | n/a | -3.11M | 5.83M | -3.08M | -3.11M | 8.32M | 34.49M |
Financial Cash Flow | 14.36M | n/a | 6.72M | 4.91M | 3.97M | -3K | 3.05M | 4.34M | 481K | -1.87M | 6M | -500K | -3.18M | -4.94M | -3.08M | -3.02M | 8.32M | 23.94M |
Net Cash Flow | 7.27M | -6.58M | 961K | -313K | -2.18M | -6.65M | -2.21M | -1.9M | -4.32M | 2.69M | 59K | -7.4M | -6.27M | -10.05M | -7.07M | -8.28M | 2.87M | 16.25M |
Free Cash Flow | -7.09M | -6.58M | -5.76M | -5.22M | -6.15M | -6.65M | -5.25M | -6.24M | -4.8M | 4.57M | -5.96M | -6.9M | -3.1M | -5.12M | -4M | -5.25M | -5.44M | -7.7M |